EyePoint Pharmaceuticals (EYPT) Stock Forecast & Price Target

EyePoint is supported by a compelling fundamental thesis built around DURAVYU’s demonstrated durability and clinical signal, including a 42% reduction in treatment burden, 76% of patients supplement-free up to Week 32, and a 4-micron central subfield thickness advantage at Week 56 versus aflibercept control. Although LUGANO missed its Phase 3 non-inferiority primary endpoint, management’s confidence in a favorable safety profile, strong anatomic outcomes, and the possibility that LUCIA can preserve a regulatory path to approval in 4Q26 provide a meaningful catalyst set. The platform has additional optionality through EYP-2301 in retinal disease and aligns with lower system costs and improved patient outcomes, while the cited upside case assigns $8 of value under selected probability assumptions.

EyePoint is viewed negatively because DURAVYU’s LUGANO study missed its prespecified primary non-inferiority endpoint in the ITT population, with the LS mean BCVA difference of -3.8 letters and the lower 95% CI bound at -5.7 letters crossing the -4.5 letter margin. The miss was driven by 9 of 211 treated patients with unusually severe non-wet AMD vision loss versus none on aflibercept, leaving questions about whether the imbalance was random or reflects a drug-related subgroup risk that could also affect LUCIA and the DME program. With a two-positive-Phase-3 path now broken, regulatory uncertainty elevated, and additional capital likely needed before profitability, the stock remains burdened by clinical, approval, and dilution risks.